Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MTEM Stock Summary
Top 10 Correlated ETFs
MTEM
In the News
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.
Molecular Templates to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences:
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)
Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today the presentation of a poster at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One-on-one meetings may be scheduled directly with Molecular Templates.
9 Hot Penny Stocks Under $0.99 To Watch Right Now
Penny stocks to watch under $1 The post 9 Hot Penny Stocks Under $0.99 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Is Molecular Templates (MTEM) Stock Up 36% Today?
Molecular Templates (NASDAQ: MTEM ) stock is rocketing higher on Friday after the company got approval from the FDA. That FDA approval has to do with its IND application for its cancer treatment.
Molecular Templates Announces Participation in Upcoming Conferences
AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, announced participation in the following upcoming 2023 conferences:
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that they will present a poster on interim clinical results for the MT-5111 program at the San Antonio Breast Cancer Symposium (SABCS) which will take place December 6 – December 10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX. Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 – December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA. In-person and virtual meetings may be scheduled directly with Molecular Templates.
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI's 5th Annual HealthCONx Conference and Piper Sandler's 34th Annual Healthcare Conference
AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that CEO, Eric Poma, Ph.D., will present a virtual fireside chat at Evercore ISI's 5th Annual HealthCONx conference which will take place November 29 – December 1, 2022, and an in-person fireside chat with an analyst Q&A portion at Piper Sandler's 34th Annual Healthcare Conference in New York, NY which will take place November 29 – December 1, 2022. Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs. One-on-one meetings may be scheduled with banking representatives of Evercore ISI or Piper Sandler, respectively, or directly with Molecular Templates.
MTEM Financial details
MTEM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.69 | 0.52 | 0.33 | 0.7 | 0.35 | |
Net income per share | -15.35 | -1.84 | -2.2 | -1.43 | -1.65 | |
Operating cash flow per share | -2.26 | -0.67 | -1.76 | -0.55 | -1.58 | |
Free cash flow per share | -5.16 | -0.92 | -1.92 | -0.62 | -1.64 | |
Cash per share | 49.64 | 3.31 | 1.97 | 2.59 | 1.08 | |
Book value per share | 51.13 | 2.73 | 1.25 | 1.19 | -0.27 | |
Tangible book value per share | 37.64 | 2.69 | 1.22 | 1.17 | -0.28 | |
Share holders equity per share | 51.13 | 2.73 | 1.25 | 1.19 | -0.27 | |
Interest debt per share | 4.87 | 0.81 | 0.65 | 0.92 | 0.98 | |
Market cap | 119.59M | 7.93B | 6.7B | 3.25B | 278.86M | |
Enterprise value | 35.12M | 7.86B | 6.71B | 3.27B | 297.25M | |
P/E ratio | -3.95 | -113.98 | -63.91 | -41 | -3.01 | |
Price to sales ratio | 16.42 | 406.49 | 428.84 | 84.02 | 14.12 | |
POCF ratio | -26.78 | -313.98 | -80.01 | -107 | -3.13 | |
PFCF ratio | -11.74 | -227.15 | -73.53 | -94.57 | -3.02 | |
P/B Ratio | 1.19 | 76.93 | 112.99 | 49.52 | -18.43 | |
PTB ratio | 1.19 | 76.93 | 112.99 | 49.52 | -18.43 | |
EV to sales | 4.82 | 402.86 | 428.96 | 84.54 | 15.05 | |
Enterprise value over EBITDA | -1.16 | -170.76 | -67.19 | -40.86 | -3.38 | |
EV to operating cash flow | -7.87 | -311.17 | -80.04 | -107.66 | -3.34 | |
EV to free cash flow | -3.45 | -225.12 | -73.55 | -95.15 | -3.22 | |
Earnings yield | -0.25 | -0.01 | -0.02 | -0.02 | -0.33 | |
Free cash flow yield | -0.09 | 0 | -0.01 | -0.01 | -0.33 | |
Debt to equity | 0.09 | 0.28 | 0.49 | 0.73 | -3.34 | |
Debt to assets | 0.06 | 0.17 | 0.21 | 0.25 | 0.52 | |
Net debt to EBITDA | 2.79 | 1.54 | -0.02 | -0.25 | -0.21 | |
Current ratio | 3.23 | 3.91 | 2.7 | 3.18 | 1.2 | |
Interest coverage | -31.31 | -54.28 | -59.14 | -23.77 | -18.58 | |
Income quality | 0.15 | 0.36 | 0.8 | 0.37 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.93 | 1.03 | 1.71 | 0.88 | 1.33 | |
Research and developement to revenue | 4.15 | 2.59 | 5.95 | 2.19 | 4.17 | |
Intangibles to total assets | 0.19 | 0.01 | 0.01 | 0.01 | 0.01 | |
Capex to operating cash flow | 1.28 | 0.38 | 0.09 | 0.13 | 0.04 | |
Capex to revenue | -0.79 | -0.49 | -0.47 | -0.1 | -0.16 | |
Capex to depreciation | -5.87 | -8.16 | -1.89 | -0.6 | -0.43 | |
Stock based compensation to revenue | 0.55 | 0.3 | 0.76 | 0.43 | 0.6 | |
Graham number | 132.88 | 10.63 | 7.86 | 6.19 | 3.15 | |
ROIC | -0.3 | -0.49 | -1 | -0.62 | -1.86 | |
Return on tangible assets | -0.27 | -0.4 | -0.76 | -0.41 | -0.96 | |
Graham Net | 30.41 | 1.67 | 0.35 | 0.3 | -0.92 | |
Working capital | 72.35M | 104.1M | 63.77M | 101.55M | 11.22M | |
Tangible asset value | 74.28M | 101.73M | 58.14M | 64.56M | -15.83M | |
Net current asset value | 65.61M | 68.73M | 20.79M | 21.52M | -44.38M | |
Invested capital | 0.09 | 0.28 | 0.49 | 0.73 | -3.34 | |
Average receivables | 120K | 3.87M | 3.87M | 117K | 0 | |
Average payables | 1.65M | 1.12M | 1.91M | 1.98M | 1.06M | |
Average inventory | 1.12M | 4.53M | 6.45M | 3.04M | 0 | |
Days sales outstanding | 12.03 | 140.54 | 5.46 | 0 | 0 | |
Days payables outstanding | 9.43 | 10.58 | 9.23 | 87.82 | 23.58 | |
Days of inventory on hand | 27.12 | 49.26 | 23.87 | 0 | 0 | |
Receivables turnover | 30.35 | 2.6 | 66.82 | 0 | 0 | |
Payables turnover | 38.72 | 34.48 | 39.56 | 4.16 | 15.48 | |
Inventory turnover | 13.46 | 7.41 | 15.29 | 0 | 0 | |
ROE | -0.3 | -0.67 | -1.77 | -1.21 | 6.13 | |
Capex per share | -2.9 | -0.26 | -0.16 | -0.07 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.08 | 0.05 | 0.6 | 1.76 | 1.33 | |
Net income per share | -0.44 | -0.39 | 0.15 | -2.89 | 0.82 | |
Operating cash flow per share | -0.43 | -0.33 | -0.34 | -2.57 | -1.48 | |
Free cash flow per share | -0.45 | -0.33 | -0.35 | -2.57 | -1.48 | |
Cash per share | 1.41 | 1.08 | 0.74 | 1.32 | 3.1 | |
Book value per share | 0.07 | -0.27 | -0.03 | -2.31 | 1.34 | |
Tangible book value per share | 0.07 | -0.28 | -0.03 | -2.31 | 1.34 | |
Share holders equity per share | 0.07 | -0.27 | -0.03 | -2.31 | 1.34 | |
Interest debt per share | 0.92 | 0.92 | 0.92 | 3.88 | 2.51 | |
Market cap | 633.95M | 278.94M | 321.2M | 27.05M | 32.19M | |
Enterprise value | 661.99M | 297.33M | 330.46M | 35.47M | 29.19M | |
P/E ratio | -6.43 | -3.16 | 9.44 | -0.62 | 1.94 | |
Price to sales ratio | 149.52 | 106.83 | 9.55 | 4.08 | 4.74 | |
POCF ratio | -25.95 | -15.13 | -16.59 | -2.81 | -4.27 | |
PFCF ratio | -24.95 | -14.88 | -16.43 | -2.8 | -4.27 | |
P/B Ratio | 152.68 | -18.43 | -168.17 | -3.12 | 4.73 | |
PTB ratio | 152.68 | -18.43 | -168.17 | -3.12 | 4.73 | |
EV to sales | 156.13 | 113.88 | 9.83 | 5.35 | 4.29 | |
Enterprise value over EBITDA | -30.73 | -14.41 | 27 | -3.79 | 5.68 | |
EV to operating cash flow | -27.1 | -16.13 | -17.07 | -3.68 | -3.87 | |
EV to free cash flow | -26.05 | -15.86 | -16.91 | -3.67 | -3.87 | |
Earnings yield | -0.04 | -0.08 | 0.03 | -0.4 | 0.13 | |
Free cash flow yield | -0.04 | -0.07 | -0.06 | -0.36 | -0.23 | |
Debt to equity | 12.12 | -3.34 | -26.35 | -1.54 | 1.88 | |
Debt to assets | 0.42 | 0.52 | 0.64 | 0.38 | 0.29 | |
Net debt to EBITDA | -1.3 | -0.89 | 0.76 | -0.9 | -0.58 | |
Current ratio | 1.74 | 1.2 | 1.73 | 0.44 | 1.06 | |
Interest coverage | -18.9 | -15.17 | 8.45 | -9.88 | -165.71 | |
Income quality | 0.99 | 0.84 | -1.79 | 0.89 | 1.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.4 | 2.33 | 0.17 | 0.78 | 0.63 | |
Research and developement to revenue | 5.18 | 6.74 | 0.57 | 2.02 | 0.84 | |
Intangibles to total assets | 0 | 0.01 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.04 | 0.02 | 0.01 | 0 | 0 | |
Capex to revenue | -0.23 | -0.12 | -0.01 | 0 | 0 | |
Capex to depreciation | -0.54 | -0.17 | -0.09 | -0.01 | 0 | |
Stock based compensation to revenue | 0.62 | 1 | 0.07 | 0.27 | 0.18 | |
Graham number | 0.85 | 1.54 | 0.34 | 12.26 | 4.95 | |
ROIC | -0.34 | -0.44 | 0.15 | -0.72 | 0.22 | |
Return on tangible assets | -0.21 | -0.23 | 0.11 | -0.31 | 0.09 | |
Graham Net | -0.62 | -0.92 | -0.63 | -9.87 | -4.21 | |
Working capital | 36.96M | 11.22M | 21.72M | -15.11M | 1.19M | |
Tangible asset value | 4.15M | -15.83M | -1.91M | -8.68M | 6.8M | |
Net current asset value | -27.31M | -44.38M | -28.79M | -32.37M | -14.56M | |
Invested capital | 12.12 | -3.34 | -26.35 | -1.54 | 1.88 | |
Average receivables | 0 | 0 | 1.42M | 1.56M | 137K | |
Average payables | 1.36M | 794.5K | 1.61M | 3.69M | 3.63M | |
Average inventory | 0 | 0 | 1M | 2.95M | 1.94M | |
Days sales outstanding | 0 | 0 | 7.6 | 3.72 | 0 | |
Days payables outstanding | 48.83 | 21.6 | 12.85 | 31.33 | 154.98 | |
Days of inventory on hand | 0 | 0 | 9.5 | 26.08 | 0 | |
Receivables turnover | 0 | 0 | 11.85 | 24.19 | 0 | |
Payables turnover | 1.84 | 4.17 | 7.01 | 2.87 | 0.58 | |
Inventory turnover | 0 | 0 | 9.48 | 3.45 | 0 | |
ROE | -5.93 | 1.46 | -4.46 | 1.25 | 0.61 | |
Capex per share | -0.02 | -0.01 | 0 | 0 | 0 |
MTEM Frequently Asked Questions
What is Molecular Templates, Inc. stock symbol ?
Molecular Templates, Inc. is a US stock , located in Austin of Tx and trading under the symbol MTEM
What is Molecular Templates, Inc. stock quote today ?
Molecular Templates, Inc. stock price is $2.24 today.
Is Molecular Templates, Inc. stock public?
Yes, Molecular Templates, Inc. is a publicly traded company.